RXRX Share Price Performance
US$3.52
-1.54 (-30.43%)
78.7% overvalued intrinsic discount
US$1.97
Fair Value
Price US$3.52
537578 US$1.97
AnalystHighTarget US$10.00
Talos US$8.38
Fair ValueUS$1.97
Share Pricen/a
Narrative Update • Jun 26
Recursion Pharmaceuticals, Inc. Stock Price
- 5 Narratives written by author
- 6 Comments on narratives written by author
- 213 Fair Values set on narratives written by author
RXRX Community Narratives
53
Fair Value
·Fair Value US$1.97 78.7% overvalued intrinsic discount
Recursion Pharmaceuticals! WTH is going on?
2users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
Fair Value
·Fair Value US$10 64.8% undervalued intrinsic discount
OS 20 Will Accelerate AI Drug Discovery And Clinical Milestones
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
TA
Fair Value
·Fair Value US$8.38 58.0% undervalued intrinsic discount
Moving from "Science Fiction" to "Science Fact" – A Bullish Valuation Case
3users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Moving from "Science Fiction" to "Science Fact" – A Bullish Valuation Case
Recursion Pharmaceuticals is currently at a critical inflection point. For years, the company was viewed as a "science project"—a high-tech platform promising to revolutionize drug discovery with AI.Read more
OS 20 Will Accelerate AI Drug Discovery And Clinical Milestones
Recursion aims to speed up how new medicines are found by combining lab automation with AI models, and recent platform upgrades could help it turn out more promising drug candidates faster. The big question is whether it can keep partnerships and clinical progress moving before cash needs, data rules, or rising competition slow things down.Read more
AN
US$10
64.8% undervalued intrinsic discount
Fair Value
Profit Margin
18.92%
Future PE
119.81x
Price in 2029
US$12.33
Advanced AI And ML Will Transform Biotech Drug Discovery
Key Takeaways Advanced AI-driven platforms and large proprietary datasets are enhancing R&D efficiency, competitive positioning, and attractiveness for pharmaceutical partnerships. Strategic focus on internal pipeline progression and industry digitization trends positions the company for sustainable revenue growth and long-term commercial upside.Read more
AN
US$7
49.7% undervalued intrinsic discount
Fair Value
Profit Margin
16.15%
Future PE
155.69x
Price in 2029
US$8.6
High R&D Burn And Regulatory Hurdles Will Cripple Future Value
Key Takeaways High R&D spending and lack of commercial assets expose the company to negative cash flow, dilution, and earnings risk. Regulatory uncertainty, revenue instability from partnerships, and increasing competition jeopardize growth, margins, and long-term market potential.Read more
AN
US$3
17.3% overvalued intrinsic discount
Fair Value
Profit Margin
16.25%
Future PE
117.8x
Price in 2028
US$3.67
Trending Discussion
Recently Updated Narratives
53
Recursion Pharmaceuticals! WTH is going on?
Fair Value: US$1.97 78.7% overvalued intrinsic discount
12 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
3 likesusers have liked this narrative
TA
Moving from "Science Fiction" to "Science Fact": Recursion’s Q4 Validates a Hyper-Growth Inflection Point
Fair Value: US$8.38 58.0% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
RXRX: AI Drug Discovery And FDA Engagement Will Set Up Cleaner Upside
Fair Value: US$10 64.8% undervalued intrinsic discount
13 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Recursion Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -1.05
- -645.61%
- -842.93%
- 1.6%
About RXRX
- Founded
- 2013
- Employees
- 600
- CEO
- WebsiteView website
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Recent RXRX News & Updates
Analysis Article • Jun 16
